2017 Biotech Charity Contest Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2017 Biotech Charity Contest

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jbogd who wrote (97)	1/4/2017 4:36:28 PM
From: ghmm	Read Replies (2) of 344

I don't disagree that may happen and perhaps people would panic sell more... But a descent number (by no means most) are trading at extremely low enterprise valuations. I own a couple near cash which have cash runways for a couple years to show some pipeline value. Will the market stay depressed for years? I also invest a lot in the rare disease area and while more and more products seem to be pricing into the ultra-orphan price range BMRN management had a couple of astute comments that I think apply to other rare disease companies: 1-The push backs in reimbursement have already happened in Europe with organizations such as NICE and IQWIG and there are single payer systems already. 2-Is it really likely that US would reimburse at a lower rate then some much less developed countries, where they are reimbursing at very similar prices (Brazil was given as an example). Additionally many biotechs don't ever get a product to market so why would drug pricing impact them :-). You had an impressive performance in the '16 contest so even in a bear bio market some do well!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next